Allianz SE Increases Stock Position in Boston Scientific Corporation $BSX

Allianz SE increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 397.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,770 shares of the medical equipment provider’s stock after buying an additional 11,000 shares during the period. Allianz SE’s holdings in Boston Scientific were worth $1,344,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. State Street Corp grew its position in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares in the last quarter. Synergy Asset Management LLC increased its holdings in shares of Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after purchasing an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC raised its position in shares of Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after buying an additional 14,700 shares in the last quarter. Finally, Channel Wealth LLC boosted its stake in Boston Scientific by 70.8% during the third quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock valued at $2,790,000 after buying an additional 11,847 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BSX. The Goldman Sachs Group set a $99.00 target price on Boston Scientific in a research note on Thursday, February 5th. Oppenheimer decreased their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a research note on Monday, February 2nd. TD Cowen cut their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Finally, Robert W. Baird lowered their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Stock Up 1.2%

BSX opened at $76.68 on Friday. Boston Scientific Corporation has a 12 month low of $72.69 and a 12 month high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The business’s 50-day moving average price is $87.31 and its 200-day moving average price is $95.60. The company has a market cap of $113.78 billion, a P/E ratio of 39.52, a P/E/G ratio of 1.06 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period last year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.